Journal: Neurodegenerative Diseases - Extended Manuscript Submission Deadline: December 31, 2024

Anti-amyloid drugs are becoming available to slow-down cognitive decline for Alzheimer’s disease, however this comes with serious medical, economic, and ethical considerations. Recent concerns about safety, particularly in patients with cerebral amyloid angiopathy and specific genotypes, also raise the question of appropriate early patient selection and exclusion.
We are calling for contributions to an article collection dedicated to emerging insights on clinical and research questions that may guide the future of these therapeutics in AD. We will consider original research articles, brief reports, protocols, guidelines, and review articles focusing on, but not strictly limited to, the following topics:

  • Biological mechanisms of action of anti-amyloid drugs
  • Epidemiological studies addressing the critical issue of patient selection
  • Economic implication and healthcare system planning 
  • Advanced neuroimaging techniques with a specific focus on amyloid-related imaging abnormalities (ARIA)


The accepted papers will be published in an article collection in Neurodegenerative Diseases entitled “Anti-amyloid drugs: a therapeutical revolution in Alzheimer’s disease.”

Please select the option “Call for Papers: Anti-amyloid Drugs: a Therapeutical Revolution in Alzheimer’s Disease” when submitting your manuscript and mention this Call for Papers in your cover letter.

Neurodegenerative Diseases is a Transformative Journal and supports Open Access publications. Publishing in this journal will ensure authors meet a plan-S style funding mandate. In addition, corresponding authors can publish Open Access articles at no or reduced cost if they are associated with or employed by one of these universities.

Check out the Author Guidelines.